Literature DB >> 16441211

Epstein-Barr virus-associated lymphomas.

Maher K Gandhi1.   

Abstract

Following Epstein and colleagues' ground-breaking discovery of Epstein-Barr virus by electron microscopy of Burkitt's lymphoma cell lines, there came the observation that Epstein-Barr virus induces immortalization of B cells in vitro. Thus, initial hopes were of a virus confined to equatorial Africa with a causal link to a particular subtype of childhood lymphoma. Over the past 40 years there has been great progress towards understanding the biology and epidemiology of Epstein-Barr virus, which conclusively show that these early ideas were overly simplistic. It is now known that Epstein-Barr virus has a seroprevalence of approximately 95% worldwide, and persists for life within host B lymphocytes. Infection in New World primates leads to lymphoma and inoculation of peripheral blood mononuclear cells from Epstein-Barr virus-seropositive subjects into severe combined immunodeficiency mice results in B-cell lymphoproliferative disorders. Epstein-Barr virus is now known to be implicated in a range of lymphoid and other malignancies, and this association will be the subject of this review.

Entities:  

Mesh:

Year:  2006        PMID: 16441211     DOI: 10.1586/14787210.4.1.77

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  12 in total

1.  EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.

Authors:  Alexandre S Cristino; Jamie Nourse; Rachael A West; Muhammed Bilal Sabdia; Soi C Law; Jay Gunawardana; Frank Vari; Sally Mujaj; Gayathri Thillaiyampalam; Cameron Snell; Madeline Gough; Colm Keane; Maher K Gandhi
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

2.  Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays.

Authors:  Isotta D'Arrigo; Emiliano Cló; Tomas Bergström; Sigvard Olofsson; Ola Blixt
Journal:  Glycoconj J       Date:  2013-01-08       Impact factor: 2.916

3.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

4.  Lymphoma after living donor kidney transplantation: an Iranian multicenter experience.

Authors:  Vahid Pourfarziani; Saeed Taheri; Mahboob Lessan-Pezeshki; Mohammad Hossein Nourbala; Naser Simforoosh; Eghlim Nemati; Khadijeh Makhdoomi; Ali Ghafari; Pedram Ahmadpour; Mohsen Nafar; Behzad Einollahi
Journal:  Int Urol Nephrol       Date:  2008-07-01       Impact factor: 2.370

5.  Comparative pathobiology of macaque lymphocryptoviruses.

Authors:  Angela Carville; Keith G Mansfield
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

6.  Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein-Barr virus infection in Nigeria population.

Authors:  Ijeoma C Uzoma; Idowu A Taiwo; Massimo Granai; Gioia Di Stefano; Ester Sorrentino; Sussana Mannucci; Muheez A Durosinmi; Stefano Lazzi; Lorenzo Leoncini; Oluyemi Akinloye
Journal:  Infect Agent Cancer       Date:  2021-05-24       Impact factor: 2.965

Review 7.  Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.

Authors:  Qingqing Cai; Kailin Chen; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

Review 8.  Gammaherpesviral Tegument Proteins, PML-Nuclear Bodies and the Ubiquitin-Proteasome System.

Authors:  Florian Full; Alexander S Hahn; Anna K Großkopf; Armin Ensser
Journal:  Viruses       Date:  2017-10-21       Impact factor: 5.048

Review 9.  STAT1 and pathogens, not a friendly relationship.

Authors:  Imen Najjar; Remi Fagard
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

10.  [Research progress on PD-1 inhibitors in lymphoma therapy].

Authors:  Y L Liu; Y Q Song; J Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.